Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Amber Blaauboer"'
Autor:
Amber Blaauboer, Stephanie Booy, Peter M. van Koetsveld, Bas Karels, Fadime Dogan, Suzanne van Zwienen, Casper H. J. van Eijck, Leo J. Hofland
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Abstract Background Adjuvant gemcitabine for pancreatic cancer has limited efficacy in the clinical setting. Impaired drug metabolism is associated with treatment resistance. We aimed to evaluate the chemosensitising effect of interferon-beta (IFN-β
Externí odkaz:
https://doaj.org/article/d7528e192b7149b28bd793a959ebfbe7
Autor:
Amber Blaauboer, Peter M. van Koetsveld, Dana A. M. Mustafa, Jasper Dumas, Fadime Dogan, Suzanne van Zwienen, Casper H. J. van Eijck, Leo J. Hofland
Publikováno v:
Biomedicines, Vol 10, Iss 3, p 517 (2022)
Background: Gemcitabine efficacy in pancreatic cancer is often impaired due to limited intracellular uptake and metabolic activation. Epi-drugs target gene expression patterns and represent a promising approach to reverse chemoresistance. In this stu
Externí odkaz:
https://doaj.org/article/96249b3ee7e54ccc9aba41e9ef64d9cb
Autor:
Amber Blaauboer, Peter Van Koetsveld, Dana Mustafa, Jasper Dumas, Fadime Dogan, Suzanne Van Zwienen, Casper Van Eijck, Leo Hofland
Publikováno v:
International Journal of Oncology, 61(2):97. Spandidos Publications
Resistance to gemcitabine is common and criti- cally limits its therapeutic efficacy in patients with pancreatic cancer. Interferon-beta (IFN-β) induces numerous antitumor effects and synergizes with gemcitabine treatment. The immunomodulatory effec
Publikováno v:
Critical Reviews in Oncology/Hematology, 159:103204. Elsevier Ireland Ltd
Immunotherapy has emerged as a new treatment strategy for cancer. However, its promise in pancreatic cancer has not yet been realized. Understanding the immunosuppressive tumor microenvironment of pancreatic cancer, and identifying new therapeutic ta
Autor:
Bas Karels, Amber Blaauboer, Casper H.J. van Eijck, Suzanne van Zwienen, Stephanie Booy, Fadime Dogan, Peter M. van Koetsveld, Leo J. Hofland
Publikováno v:
BMC Cancer
BMC Cancer, 20(1):913. BioMed Central Ltd.
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
BMC Cancer, 20(1):913. BioMed Central Ltd.
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Background Adjuvant gemcitabine for pancreatic cancer has limited efficacy in the clinical setting. Impaired drug metabolism is associated with treatment resistance. We aimed to evaluate the chemosensitising effect of interferon-beta (IFN-β). Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6c34c37deae3142c65fd2f1f4f2f8a1
https://doi.org/10.21203/rs.3.rs-39801/v3
https://doi.org/10.21203/rs.3.rs-39801/v3
Autor:
Casper H.J. van Eijck, Leo J. Hofland, Peter M. van Koetsveld, Bas Karels, Stephanie Booy, Suzanne vanZwienen, Fadime Dogan, Amber Blaauboer
Publikováno v:
Advances in Cancer Research & Clinical Imaging. 2
Publikováno v:
HPB. 20:S245